Skip to main content
. 2020 Sep 14;20:1400. doi: 10.1186/s12889-020-09497-5

Table 2.

Multivariable-adjusted mean changes in cardiovascular disease risk factors (95% CI) over 6 years of follow-up, according to quartiles of sedentary time and meeting guidelines for moderate-to-vigorous physical activity (N ~ 7900, 2 h glucose N ~ 5800)a (No exclusions)

Change in CVD risk factors Sedentary time P-trend MVPA guidelinesb P
Quartile 1
(0.8–10.8 h)
Quartile 2
(10.8–12.0 h)
Quartile 3
(12.0–13.0 h)
Quartile 4
(13.0–16.0 h)
Not meet Meet
BMI, kg/m2
Model 1 0.69 (0.50, 0.88) 0.83 (0.63, 1.04) 0.54 (0.34, 0.73) 0.68 (0.50, 0.87) 0.53 0.65 (0.53, 0.78) 0.73 (0.57, 0.89) 0.39
Model 2 0.67 (0.47, 0.87) 0.80 (0.60, 1.01) 0.55 (0.36, 0.74) 0.69 (0.50, 0.88) 0.75 0.62 (0.49, 0.74) 0.76 (0.60, 0.92) 0.16
Model 3 0.63 (0.41, 0.84) 0.80 (0.60, 1.00) 0.56 (0.37, 0.75) 0.73 (0.53, 0.92) 0.83 0.61 (0.47, 0.74) 0.77 (0.60, 0.93) 0.14
Waist circumference, cm
Model 1 2.22 (1.72, 2.72) 2.23 (1.64, 2.81) 1.78 (1.16, 2.41) 2.96 (2.41, 3.52) 0.19 2.12 (1.74, 2.49) 2.53 (2.10, 2.96) 0.13
Model 2 2.36 (1.83, 2.89) 2.30 (1.71, 2.89) 1.84 (1.26, 2.43) 2.57 (2.01, 3.12) 0.97 2.25 (1.87, 2.63) 2.29 (1.87, 2.72) 0.88
Model 3 2.35 (1.78, 2.93) 2.30 (1.71, 2.89) 1.85 (1.26, 2.43) 2.57 (2.00, 3.15) 0.93 2.22 (1.82, 2.62) 2.33 (1.89, 2.77) 0.71
Systolic BP, mmHg
Model 1 0.89 (0.14, 1.65) 1.39 (0.51, 2.27) 0.84 (0.01, 1.66) 0.69 (−0.13, 1.52) 0.60 0.94 (0.35, 1.52) 0.97 (0.31, 1.63) 0.94
Model 2 0.84 (0.02, 1.66) 1.45 (0.59, 2.30) 0.97 (0.15, 1.79) 0.59 (−0.24, 1.43) 0.64 1.04 (0.43, 1.65) 0.86 (0.21, 1.51) 0.68
Model 3 1.01 (0.13, 1.89) 1.45 (0.60, 2.30) 0.93 (0.10, 1.75) 0.46 (−0.38, 1.31) 0.34 1.05 (0.42, 1.68) 0.85 (0.15, 1.54) 0.69
Diastolic BP, mmHg
Model 1 −0.17 (− 0.78, 0.45) 0.30 (− 0.32, 0.93) −0.02 (− 0.66, 0.61) 0.26 (− 0.40, 0.93) 0.45 −0.14 (− 0.60, 0.32) 0.39 (− 0.12, 0.89) 0.115
Model 2 − 0.06 (− 0.69, 0.58) 0.47 (− 0.15, 1.08) 0.06 (− 0.55, 0.68) −0.18 (− 0.85, 0.49) 0.73 0.01 (− 0.45, 0.47) 0.15 (− 0.36, 0.66) 0.67
Model 3 0.04 (− 0.65, 0.73) 0.48 (− 0.14, 1.09) 0.03 (− 0.59, 0.64) −0.25 (− 0.92, 0.43) 0.48 0.04 (− 0.45, 0.52) 0.11 (− 0.44, 0.67) 0.84
LDL-cholesterol, mg/dl
Model 1 −5.22 (−6.91, −3.53) −3.89 (−5.97, −1.81) −4.63 (− 6.64, −2.62) −4.68 (− 6.70, − 2.67) 0.74 − 4.39 (− 5.74, − 3.03) − 4.88 (− 6.32, − 3.44) 0.59
Model 2 −5.79 (−7.53, − 4.05) −3.91 (− 6.03, − 1.79) −4.25 (− 6.23, − 2.26) −4.61 (− 6.48, − 2.74) 0.36 −4.21 (− 5.51, − 2.91) − 5.18 (− 6.64, − 3.71) 0.28
Model 3 −5.94 (− 7.82, − 4.07) −3.92 (− 6.05, − 1.79) − 4.12 (− 6.13, − 2.12) − 4.56 (− 6.46, − 2.67) 0.32 − 4.48 (− 5.83, − 3.12) −4.85 (− 6.39, − 3.31) 0.71
HDL-cholesterol, mg/dl
Model 1 1.27 (0.60, 1.94) 1.32 (0.72, 1.93) 2.17 (1.43, 2.90) 1.39 (0.76, 2.02) 0.42 1.61 (1.17, 2.06) 1.44 (0.93, 1.94) 0.61
Model 2 1.66 (0.94, 2.37) 1.34 (0.77, 1.91) 2.01 (1.31, 2.70) 1.12 (0.47, 1.77) 0.56 1.71 (1.25, 2.16) 1.31 (0.80, 1.82) 0.27
Model 3 1.80 (1.00, 2.59) 1.35 (0.79, 1.92) 1.99 (1.29, 2.70) 0.99 (0.30, 1.67) 0.34 1.69 (1.21, 2.17) 1.33 (0.78, 1.88) 0.37
Triglycerides, mg/dl c
Model 1 0.96 (0.92, 1.00) 0.93 (0.89, 0.96) 0.94 (0.91, 0.97) 0.95 (0.92, 0.98) 0.77 0.94 (0.92, 0.96) 0.95 (0.92, 0.97) 0.58
Model 2 0.94 (0.91, 0.98) 0.93 (0.89, 0.96) 0.94 (0.91, 0.97) 0.96 (0.93, 0.99) 0.58 0.94 (0.92, 0.96) 0.95 (0.93, 0.98) 0.30
Model 3 0.94 (0.90, 0.98) 0.93 (0.89, 0.96) 0.94 (0.91, 0.97) 0.96 (0.93, 1.00) 0.27 0.93 (0.91, 0.96) 0.95 (0.93, 0.98) 0.29
Fasting glucose, mg/dl
Model 1 3.86 (2.94, 4.78) 4.26 (3.29, 5.22) 4.14 (3.08, 5.20) 4.33 (3.30, 5.35) 0.52 4.84 (4.14, 5.54) 3.29 (2.54, 4.04) 0.001
Model 2 3.47 (2.46, 4.48) 4.04 (3.08, 5.01) 4.34 (3.27, 5.41) 4.79 (3.76, 5.83) 0.072 4.63 (3.94, 5.33) 3.58 (2.83, 4.34) 0.03
Model 3 3.55 (2.46, 4.64) 4.09 (3.12, 5.06) 4.20 (3.12, 5.29) 4.81 (3.73, 5.88) 0.142 4.73 (4.03, 5.44) 3.46 (2.64, 4.28) 0.01
2-h glucose, mg/dl
Model 1 7.57 (5.03, 10.10) 8.22 (5.59, 10.84) 7.06 (3.96, 10.16) 9.78 (7.21, 12.34) 0.37 8.17 (6.38, 9.96) 8.08 (6.04, 10.12) 0.94
Model 2 7.01 (4.48, 9.53) 8.21 (5.56, 10.85) 7.62 (4.63, 10.61) 9.86 (7.32, 12.39) 0.17 8.43 (6.72, 10.14) 7.80 (5.76, 9.83) 0.59
Model 3 7.48 (4.87, 10.09) 8.38 (5.72, 11.03) 7.23 (4.23, 10.23) 9.55 (6.82, 12.29) 0.43 8.29 (6.52, 10.06) 7.96 (5.87, 10.04) 0.79
HbA1c, mg/dl
Model 1 0.18 (0.15, 0.21) 0.18 (0.15, 0.21) 0.15 (0.12, 0.18) 0.17 (0.14, 0.20) 0.28 0.16 (0.15, 0.18) 0.18 (0.15, 0.20) 0.28
Model 2 0.18 (0.15, 0.21) 0.18 (0.15, 0.21) 0.16 (0.13, 0.19) 0.17 (0.14, 0.20) 0.51 0.17 (0.15, 0.18) 0.18 (0.16, 0.20) 0.35
Model 3 0.18 (0.15, 0.21) 0.18 (0.15, 0.21) 0.16 (0.13, 0.19) 0.17 (0.14, 0.20) 0.69 0.17 (0.15, 0.19) 0.17 (0.15, 0.20) 0.98
Fasting insulin, mU/L c
Model 1 1.20 (1.15, 1.25) 1.23 (1.18, 1.30) 1.19 (1.14, 1.24) 1.21 (1.16, 1.25) 0.82 1.23 (1.20, 1.27) 1.18 (1.14, 1.22) 0.02
Model 2 1.18 (1.13, 1.23) 1.22 (1.17, 1.28) 1.20 (1.15, 1.25) 1.23 (1.19, 1.28) 0.13 1.22 (1.19, 1.26) 1.19 (1.14, 1.23) 0.10
Model 3 1.19 (1.13, 1.24) 1.23 (1.17, 1.29) 1.19 (1.14, 1.24) 1.22 (1.18, 1.27) 0.55 1.23 (1.19, 1.26) 1.18 (1.14, 1.23) 0.06
HOMA-IR c
Model 1 1.27 (1.21, 1.32) 1.29 (1.22, 1.36) 1.24 (1.18, 1.30) 1.25 (1.20, 1.31) 0.55 1.29 (1.25, 1.33) 1.23 (1.18, 1.27) 0.02
Model 2 1.23 (1.17, 1.28) 1.27 (1.21, 1.34) 1.25 (1.19, 1.31) 1.29 (1.24, 1.34) 0.13 1.28 (1.24, 1.32) 1.24 (1.19, 1.29) 0.13
Model 3 1.24 (1.18, 1.31) 1.28 (1.21, 1.35) 1.24 (1.18, 1.30) 1.28 (1.23, 1.33) 0.55 1.28 (1.24, 1.32) 1.23 (1.18, 1.28) 0.07

aExtreme values of change in biomarker (>3SD of distribution) were excluded; extreme observations differ according to different biomarkers- so sample size is different for analysis of each biomarker

Model 1 adjusted for age at baseline, sex, use of medications that affect the dependent variable at baseline and/or visit2, baseline levels of the dependent variable, and elapsed time between visits

Model 2 further adjusted for baseline household income, education, employment status, Hispanic/Latino background, field center, and nativity status, smoking, alcohol consumption, health insurance status, healthcare utilization, self-reported health, diet quality, change in health insurance, baseline BMI and waist-hip ratio (except in modeling change of BMI and waist circumference)

Model 3 adjusted for Model 2 covariates and sedentary time in models of MVPA or MVPA in models of sedentary time

bMeeting 2018 physical activity guidelines defined using measured activity scaled to 7 days of accelerometer wear as 150 minutes/week moderate intensity physical activity, 75 minutes/week vigorous intensity activity, or an equivalent combination of both

cGeometric means (95% CI) presented for triglycerides, fasting insulin, HOMA-IR

Significant findings p < 0.05 bolded